LIVTENCITY▼® (maribavir) safety data
An overview of the safety and tolerability profile of LIVTENCITY
A discussion of the outcomes of the phase III SOLSTICE trial featured in this video:
• Dr Sowsan Atabani (Consultant Virologist, UK Health Security Agency and University Hospitals Birmingham)
• Mr Colin Wilson (Consultant Transplant and Hepatobiliary Surgeon, Newcastle Hospitals)
LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).1
Consideration should be given to official guidance on the appropriate use of antiviral agents.1
Book a meeting
Click this link to discuss the information on this page further with a Takeda representative.
In the SOLSTICE trial, LIVTENCITY delivered double the viraemia clearance (55.7%) compared to investigator-assigned therapy (IAT) (23.9%) – primary endpoint2
Confirmed viraemia clearance* of refractory CMV in all transplants (HSCT and SOT) at Study Week 82
*Plasma CMV DNA <137 IU/mL in 2 consecutive tests ≥5 days apart.2
LIVTENCITY — positive safety profile in post-transplant refractory CMV (with or without resistance)
Fewer treatment emergent adverse events leading to discontinuation than IAT: 13.2% [31/234] of transplant recipients treated with LIVTENCITY experienced a TEAE that led to discontinuation (vs 31.9% [37/116] in those who received investigator assigned therapies)3
LIVTENCITY treatment-related adverse events compared to IAT2,3
In the SOLSTICE trial, the most reported treatment-related adverse event was dysgeusia (35.9% [84/234] vs 0.9% [1/116] receiving IAT) that typically resolved during or after treatment.3